In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleriamellonella model

References

• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582.
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35:219–226.
   PubMed Web of Science ®Google Scholar
• Hornsey M, Ellington MJ, Doumith M, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:1589–1593.
   PubMed Web of Science ®Google Scholar
• Park YK, Jung SI, Park KH, et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis. 2009;64:43–51.
   PubMed Web of Science ®Google Scholar
• Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:1163–1167.
   PubMed Web of Science ®Google Scholar
• Rodriguez CH, Bombicino K, Granados G, et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188–191.
   PubMed Web of Science ®Google Scholar
• Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;60:421–423.
   PubMed Web of Science ®Google Scholar
• Tripodi MF, Durante-Mangoni E, Fortunato R, et al. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents. 2007;30:537–540.
   PubMed Web of Science ®Google Scholar
• Wareham DW, Bean DC. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob. 2006;5:10. doi:10.1186/1476-0711-5-10.
   PubMedGoogle Scholar
• Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:5316–5322.
   PubMed Web of Science ®Google Scholar
• Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55:3534–3537.
   PubMed Web of Science ®Google Scholar
• Champion OL, Cooper IA, James SL, et al. Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology. 2009;155:1516–1522.
   PubMed Web of Science ®Google Scholar
• Jander G, Rahme LG, Ausubel FM. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J Bacteriol. 2000;182:3843–3845.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Reeves EP. Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens. FEMS Microbiol Rev. 2004;28:101–112.
   PubMed Web of Science ®Google Scholar
• Bryson V, Szybalski W. Microbial selection. Science. 1952;116:45–51.
   Web of Science ®Google Scholar
• Woodford N, Ellington MJ, Coelho JM, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–353.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing; Twenty-Fourth informational supplement, M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections, a prospective, open-label, uncontrolled study. Clin Ther. 2008;30:143–151.
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53:1863–1867.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Jara S, Monga D, et al. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother. 2009;53:2605–2609.
   PubMed Web of Science ®Google Scholar
• Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am J Health Syst Pharm. 2007;64:2462–2466.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275–1279.
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin–resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56:4856–4861.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55:5685–5695.
   PubMed Web of Science ®Google Scholar
• O’Hara JA, Ambe LA, Casella LG, et al. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2013;5:2103–2108.
   Web of Science ®Google Scholar